

Use of IDegLira to intensify, simplify, increase appropriateness of type 2 diabetes therapy: a real life experience

Authors: Isabella Romano, Rosalia Serra

Affiliation: U.O.S.V.D. Endocrinology/Diabetology - Cittadella della Salute, ASL Lecce, Italy

Corresponding author:

Isabella Romano

U.O.S.V.D. Endocrinology/Diabetology - Cittadella della Salute, ASL Lecce, Italy

Email: isa.romano@yahoo.it, diabetologia.dis1lecce@asl.lecce.it

Supplementary table 1: Changes in the use of classes of diabetes treatment at the first prescription of IDegLira by previous treatment scheme

	OHA (N=19)			GLP1-RA (N=5)			BOT (N=41)			BB (N=22)		
Time	T-1	T0	p-value	T-1	T0	p-value	T-1	T0	p-value	T-1	T0	p-value
Metformin	89.5	84.2	0.56	-	-	-	63.4	78.1	0.01	22.7	81.8	0.0008
Secretagogues	89.5	5.3	<0.0001	-	-	-	56.1	9.8	<0.0001	4.6	4.6	1.00
Pioglitazone	0	5.3	1.00	-	-	-	4.9	4.9	1.00	0	4.6	1.00
DPP4i	42.1	0	<0.0001	-	-	-	26.8	0	0.001	-	-	-
SGLT2i	10.5	0	0.5	-	-	-	4.9	0	0.50	0	4.6	1.00
Acarbose	-	-	-	-	-	-	-	-	-	-	-	-
No. OHAs (%)			0.07	-	-	-			0.57			0.0001
0	0	10.5		-	-	-	0	14.6		72.7	4.6	
1	5.3	84.2		-	-	-	43.9	78.1		27.3	95.5	
2	57.9	5.3		-	-	-	56.1	7.3		-	-	
3	36.8	0		-	-	-	0	0		-	-	

*McNemar test; statistical significant p-values (<0.05) are in bold text